{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:46Z","timestamp":1792804186633,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sophia Children\u2019s Hospital Foundation","award":["S-687"],"award-info":[{"award-number":["S-687"]}]},{"name":"Prinses Beatrix Spierfonds\/Stichting Spieren voor Spieren","award":["W.OR13-21"],"award-info":[{"award-number":["W.OR13-21"]}]},{"name":"Tex net"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.omtn.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T06:30:32Z","timestamp":1489473032000},"page":"101-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells"],"prefix":"10.1016","volume":"7","author":[{"given":"Erik","family":"van der Wal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atze J.","family":"Bergsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.M.","family":"van Gestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.M.","family":"in \u2018t Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm","family":"Zaehres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos J.","family":"Ara\u00fazo-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans R.","family":"Sch\u00f6ler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.W.M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2017.03.002_bib1","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1093\/nar\/15.17.7155","article-title":"RNA splice junctions of different classes of\u00a0eukaryotes: sequence statistics and functional implications in gene expression","volume":"15","author":"Shapiro","year":"1987","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.03.002_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/gbe\/evw025","article-title":"Evolutionary insights into RNA trans-splicing in vertebrates","volume":"8","author":"Lei","year":"2016","journal-title":"Genome Biol. Evol."},{"key":"10.1016\/j.omtn.2017.03.002_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2014.09.054","article-title":"Building robust transcriptomes with master splicing factors","volume":"159","author":"Jangi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2017.03.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-013-1358-4","article-title":"The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine","volume":"133","author":"Stenson","year":"2014","journal-title":"Hum Genet."},{"key":"10.1016\/j.omtn.2017.03.002_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtn.2017.03.001","article-title":"Antisense oligonucleotides promote exon inclusion and correct the common c.-32-13T > G (IVS1) GAA splicing variant in Pompe disease","volume":"7","author":"Van der Wal","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2017.03.002_bib6","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2017.03.002_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl\u00a01","key":"10.1016\/j.omtn.2017.03.002_bib8","first-page":"114","article-title":"New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond","volume":"12","author":"Kishnani","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.omtn.2017.03.002_bib9","article-title":"Survival and long-term outcomes in late-onset Pompe\u00a0disease following alglucosidase alfa treatment: a systematic review and meta-analysis","author":"Schoser","year":"2016","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtn.2017.03.002_bib10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2017.03.002_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36\u00a0months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2017.03.002_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2017.03.002_bib13","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation","volume":"3","author":"Huie","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2017.03.002_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2017.03.002_bib15","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.03.002_bib16","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2017.03.002_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.stemcr.2013.10.007","article-title":"Derivation and FACS-mediated purification of PAX3+\/PAX7+ skeletal muscle precursors from human pluripotent stem cells","volume":"1","author":"Borchin","year":"2013","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.omtn.2017.03.002_bib18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/mt.2010.314","article-title":"Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming","volume":"19","author":"Warlich","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2017.03.002_bib19","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/hmg\/3.12.2213","article-title":"The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II","volume":"3","author":"Hermans","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2017.03.002_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/humu.10286","article-title":"Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II","volume":"23","author":"Hermans","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2017.03.002_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.diff.2013.01.001","article-title":"Polycistronic lentivirus induced pluripotent stem cells from skin biopsies after long\u00a0term storage, blood outgrowth endothelial cells and cells from milk teeth","volume":"85","author":"Dambrot","year":"2013","journal-title":"Differentiation"},{"key":"10.1016\/j.omtn.2017.03.002_bib22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1083\/jcb.105.2.949","article-title":"Growth factor control of skeletal muscle differentiation: commitment to terminal differentiation occurs in G1 phase and is repressed by fibroblast growth factor","volume":"105","author":"Clegg","year":"1987","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtn.2017.03.002_bib23","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.3390\/ijms16034429","article-title":"Mammalian introns: when the junk generates molecular diversity","volume":"16","author":"Hub\u00e9","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2017.03.002_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymgme.2014.02.012","article-title":"The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-\u03b1-glucosidase in Pompe\u2019s iPSCs","volume":"112","author":"Higuchi","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtn.2017.03.002_bib25","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1074\/jbc.M114.628628","article-title":"Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes","volume":"290","author":"Raval","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.03.002_bib26","article-title":"Metabolomic profiling of pompe disease-induced pluripotent stem cell-derived cardiomyocytes reveals that oxidative stress is associated with cardiac and skeletal muscle pathology","author":"Sato","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.omtn.2017.03.002_bib27","doi-asserted-by":"crossref","first-page":"16054","DOI":"10.1038\/mtm.2016.54","article-title":"TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle","volume":"3","author":"Sato","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2017.03.002_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCGENETICS.115.001322","article-title":"Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in Pompe disease","volume":"9","author":"Wens","year":"2016","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.omtn.2017.03.002_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2008.07.013","article-title":"Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities","volume":"275","author":"van der Beek","year":"2008","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.omtn.2017.03.002_bib30","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.0000000000002523","article-title":"Cognitive decline in classic infantile Pompe disease: An underacknowledged challenge","volume":"86","author":"Ebbink","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2017.03.002_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1750-1172-8-182","article-title":"Phenotypical variation within 22 families with Pompe disease","volume":"8","author":"Wens","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2017.03.002_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0022-510X(87)90239-5","article-title":"Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid alpha-glucosidase","volume":"79","author":"van der Ploeg","year":"1987","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.omtn.2017.03.002_bib33","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.celrep.2016.05.016","article-title":"Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model","volume":"15","author":"Choi","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2017.03.002_bib34","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/nbt.3297","article-title":"Differentiation of pluripotent\u00a0stem cells to muscle fiber to model Duchenne muscular dystrophy","volume":"33","author":"Chal","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2017.03.002_bib35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5966\/sctm.2013-0143","article-title":"Derivation of myogenic progenitors directly from human pluripotent stem cells using a sphere-based culture","volume":"3","author":"Hosoyama","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.omtn.2017.03.002_bib36","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.5966\/sctm.2015-0224","article-title":"A human pluripotent stem cell model of facioscapulohumeral muscular dystrophy-affected skeletal muscles","volume":"5","author":"Caron","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.omtn.2017.03.002_bib37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.stemcr.2014.07.001","article-title":"Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells","volume":"3","author":"Shelton","year":"2014","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.omtn.2017.03.002_bib38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.cell.2013.10.023","article-title":"A zebrafish embryo culture system defines factors that promote vertebrate myogenesis across species","volume":"155","author":"Xu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2017.03.002_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ymeth.2015.09.019","article-title":"Robust generation and expansion of skeletal muscle progenitors and myocytes from human pluripotent stem cells","volume":"101","author":"Shelton","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.omtn.2017.03.002_bib40","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/mtna.2016.75","article-title":"From cryptic toward canonical pre-mRNA splicing in Pompe disease: a pipeline for the development of antisense oligonucleotides","volume":"5","author":"Bergsma","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2017.03.002_bib41","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2017.03.002_bib42","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2017.03.002_bib43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.nmd.2013.06.369","article-title":"194th ENMC international workshop. 3rd ENMC workshop on exon skipping: towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands","volume":"23","author":"Aartsma-Rus","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2017.03.002_bib44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","article-title":"Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy","volume":"15","author":"Straub","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2017.03.002_bib45","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.03.002_bib46","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1038\/ncomms10981","article-title":"Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice","volume":"7","author":"Han","year":"2016","journal-title":"Nat. Commun."},{"issue":"Pt A","key":"10.1016\/j.omtn.2017.03.002_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","article-title":"Peptides for nucleic acid delivery","volume":"106","author":"Lehto","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2017.03.002_bib48","doi-asserted-by":"crossref","first-page":"20832","DOI":"10.1038\/srep20832","article-title":"Impact of different cell penetrating peptides on the efficacy of antisense therapeutics for targeting intracellular pathogens","volume":"6","author":"Abushahba","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2017.03.002_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2015.02.008","article-title":"Delivery of therapeutic oligonucleotides with cell penetrating peptides","volume":"87","author":"Boisgu\u00e9rin","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2017.03.002_bib50","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11011-013-9434-y","article-title":"Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases","volume":"28","author":"Liu","year":"2013","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.omtn.2017.03.002_bib51","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of Affymetrix GeneChip probe level data","volume":"31","author":"Irizarry","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2017.03.002_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/humu.22705","article-title":"Identification and characterization of aberrant GAA pre-mRNA splicing in pompe disease using a generic approach","volume":"36","author":"Bergsma","year":"2015","journal-title":"Hum. Mutat."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T11:24:08Z","timestamp":1535973848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253117301403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":52,"alternative-id":["S2162253117301403"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2017.03.002","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2017.03.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s).","name":"copyright","label":"Copyright"}]}}